Recently, it has been shown that glucagon receptor agonists are effective in the treatment of obesity and T2D by increasing energy expenditure and inhibiting food intake, despite their hyperglycaemic effects (Novikoff and Müller 2023). Here, GCGR is linked to obesity due to melanocortin 4 receptor deficiency.